AMMOL
MCID: ACT193
MIFTS: 59

Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22) (AMMOL)

Categories: Blood diseases, Bone diseases, Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils...

MalaCards integrated aliases for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22):

Name: Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22) 54 60
Acute Myelomonocytic Leukemia 54 60 30 17 74
Aml with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22) 54 60
Aml M4 54 60
Ammol 54 60
Aml with Inv(16)(p13.1q22) or T(16;16)(p13.1;q22) 54
Acute Myeloblastic Leukemia Type 4 54
Leukemia, Acute Myelomonocytic 13
Leukemia Myelomonocytic Acute 56
Cbfb-Myh11 54
Aml-M4 54

Characteristics:

Orphanet epidemiological data:

60
acute myelomonocytic leukemia
Inheritance: Not applicable; Age of onset: Adult;

Classifications:



External Ids:

ICD10 34 C92.5
MESH via Orphanet 46 D015479
ICD10 via Orphanet 35 C92.5
UMLS via Orphanet 75 C0023479
UMLS 74 C0023479

Summaries for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils...

NIH Rare Diseases : 54 Acute myelomonocytic leukemia (AMML) is a cancer that typically develops in the bone marrow and blood of older individuals.  AMML is one type of acute myeloid leukemia, a group of blood cancers that occur when the amount of white blood cells increases rapidly.  Symptoms of AMML often include fatigue (due to anemia) or easy bruising or bleeding (due to thrombocytopenia).  The cause of AMML is currently unknown.  Treatment typically consists of chemotherapy.

MalaCards based summary : Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22), also known as acute myelomonocytic leukemia, is related to leukemia and ring chromosome 21, and has symptoms including fever and fatigue. An important gene associated with Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22) is CBFB (Core-Binding Factor Subunit Beta), and among its related pathways/superpathways are PAK Pathway and PI3K-Akt signaling pathway. The drugs Lenograstim and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Related Diseases for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils...

Diseases related to Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22) via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 112)
# Related Disease Score Top Affiliating Genes
1 leukemia 30.8 CREBBP ETV6 FLT3 KIT RUNX1
2 ring chromosome 21 30.1 ETV6 KMT2A
3 myeloid sarcoma 30.0 DNTT FLT3 KIT KMT2A MPO
4 lymphocytic leukemia 29.7 DNTT ETV6 KMT2A RUNX1
5 leukemia, acute monocytic 29.7 CREBBP KMT2A MPO
6 acute promyelocytic leukemia 29.6 CSF1R FLT3 MPO RUNX1
7 aleukemic leukemia cutis 29.5 FLT3 MPO MYH11 RUNX1
8 malignant histiocytosis 29.2 CSF1 CSF1R
9 leukemia, acute lymphoblastic 29.0 DNTT ETV6 FLT3 KMT2A RUNX1
10 chronic myelomonocytic leukemia 29.0 CSF1 ETV6 FLT3 KIT RUNX1
11 myeloid leukemia 28.7 CBFB CREBBP ETV6 FLT3 KIT MYH11
12 leukemia, chronic myeloid 28.6 DNTT ETV6 FLT3 KIT KMT2A MPO
13 leukemia, acute myeloid 28.5 CBFB CSF1R DNTT ETV6 FLT3 KIT
14 acute leukemia 27.9 CREBBP DNTT ETV6 FLT3 KIT KMT2A
15 myelodysplastic syndrome 27.6 CREBBP CSF1 CSF1R DNTT ETV6 FLT3
16 sarcoma 10.4
17 acute myeloblastic leukemia with maturation 10.3 FLT3 KIT
18 myeloma, multiple 10.3
19 acute myeloid leukemia with minimal differentiation 10.3 FLT3 MPO
20 mast-cell sarcoma 10.2 KIT MPO
21 cytogenetically normal acute myeloid leukemia 10.2 FLT3 KMT2A
22 chronic eosinophilic leukemia 10.2 FLT3 KIT
23 uterine inversion 10.2 CSF1R KIT
24 lymphoma 10.2
25 acute basophilic leukemia 10.1 ETV6 MPO
26 mycosis fungoides 10.1
27 vasculitis 10.1
28 polymorphous low-grade adenocarcinoma 10.1 KIT MYH11
29 congenital mesoblastic nephroma 10.1 ETV6 KIT
30 b-cell childhood acute lymphoblastic leukemia 10.1 ETV6 RUNX1
31 leukemia, chronic lymphocytic 2 10.0
32 leukemia, chronic lymphocytic 10.0
33 fanconi anemia, complementation group a 10.0
34 leukostasis 10.0
35 macroglobulinemia 10.0
36 hypereosinophilic syndrome 10.0
37 leukemia, b-cell, chronic 10.0
38 pdgfrb-associated chronic eosinophilic leukemia 10.0
39 tetrasomy 21 10.0 DNTT RUNX1
40 neonatal leukemia 10.0 CREBBP FLT3
41 graft-versus-host disease 10.0
42 acute graft versus host disease 10.0
43 xp22.3 microdeletion syndrome 10.0
44 platelet disorder, familial, with associated myeloid malignancy 10.0 ETV6 RUNX1
45 lymphoid leukemia 10.0 ETV6 FLT3 KMT2A
46 acute myeloid leukemia with t(8;21)(q22;q22) translocation 10.0 FLT3 KIT RUNX1
47 8p11 myeloproliferative syndrome 10.0 FLT3 KIT RUNX1
48 dendritic cell tumor 10.0 DNTT MPO
49 acute biphenotypic leukemia 10.0 DNTT KMT2A MPO
50 malignant mesenchymoma 10.0 ETV6 KIT

Graphical network of the top 20 diseases related to Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22):



Diseases related to Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22)

Symptoms & Phenotypes for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils...

UMLS symptoms related to Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22):


fever, fatigue

GenomeRNAi Phenotypes related to Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22) according to GeneCards Suite gene sharing:

27 (show all 33)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.4 MPO
2 Increased shRNA abundance (Z-score > 2) GR00366-A-102 10.4 DNTT FLT3 KIT
3 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.4 FLT3
4 Increased shRNA abundance (Z-score > 2) GR00366-A-116 10.4 FLT3
5 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.4 FLT3
6 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.4 FLT3
7 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.4 FLT3
8 Increased shRNA abundance (Z-score > 2) GR00366-A-123 10.4 DNTT FLT3
9 Increased shRNA abundance (Z-score > 2) GR00366-A-126 10.4 MPO
10 Increased shRNA abundance (Z-score > 2) GR00366-A-138 10.4 DNTT
11 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.4 DNTT
12 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.4 KIT
13 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.4 DNTT KIT MPO
14 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.4 DNTT
15 Increased shRNA abundance (Z-score > 2) GR00366-A-163 10.4 FLT3
16 Increased shRNA abundance (Z-score > 2) GR00366-A-170 10.4 KIT
17 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.4 MPO
18 Increased shRNA abundance (Z-score > 2) GR00366-A-182 10.4 DNTT
19 Increased shRNA abundance (Z-score > 2) GR00366-A-186 10.4 MPO
20 Increased shRNA abundance (Z-score > 2) GR00366-A-197 10.4 DNTT
21 Increased shRNA abundance (Z-score > 2) GR00366-A-25 10.4 FLT3
22 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.4 MPO
23 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.4 KIT
24 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.4 MPO
25 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.4 KIT
26 Increased shRNA abundance (Z-score > 2) GR00366-A-57 10.4 MPO
27 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.4 MPO
28 Increased shRNA abundance (Z-score > 2) GR00366-A-70 10.4 FLT3 MPO
29 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.4 DNTT
30 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.4 KIT
31 Increased shRNA abundance (Z-score > 2) GR00366-A-9 10.4 KIT
32 Increased shRNA abundance (Z-score > 2) GR00366-A-99 10.4 KIT
33 Reduced mammosphere formation GR00396-S 9.02 CSF1 CSF1R ETV6 KMT2A RUNX1

MGI Mouse Phenotypes related to Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22):

47 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.29 CBFB CREBBP CSF1 CSF1R DNTT ETV6
2 cellular MP:0005384 10.27 CBFB CREBBP CSF1 CSF1R ETV6 FLT3
3 hematopoietic system MP:0005397 10.26 CBFB CREBBP CSF1 CSF1R DNTT ETV6
4 cardiovascular system MP:0005385 10.24 CBFB CREBBP CSF1 ETV6 KIT KMT2A
5 growth/size/body region MP:0005378 10.24 CBFB CREBBP CSF1 CSF1R ETV6 FLT3
6 immune system MP:0005387 10.24 CBFB CREBBP CSF1 CSF1R DNTT ETV6
7 endocrine/exocrine gland MP:0005379 10.15 CBFB CREBBP CSF1 CSF1R ETV6 FLT3
8 mortality/aging MP:0010768 10.14 CBFB CREBBP CSF1 CSF1R ETV6 FLT3
9 integument MP:0010771 10.13 CBFB CREBBP CSF1 CSF1R ETV6 KIT
10 craniofacial MP:0005382 10.04 CBFB CREBBP CSF1 CSF1R KIT KMT2A
11 embryo MP:0005380 10.03 CBFB CREBBP ETV6 KIT KMT2A RUNX1
12 limbs/digits/tail MP:0005371 9.93 CBFB CREBBP CSF1 CSF1R KIT KMT2A
13 liver/biliary system MP:0005370 9.91 CBFB CREBBP CSF1 KIT KMT2A RUNX1
14 neoplasm MP:0002006 9.87 CBFB CREBBP ETV6 FLT3 KIT KMT2A
15 no phenotypic analysis MP:0003012 9.86 CBFB CSF1 CSF1R ETV6 FLT3 KIT
16 muscle MP:0005369 9.85 CREBBP CSF1 KIT KMT2A MPO MYH11
17 normal MP:0002873 9.76 CBFB CREBBP CSF1R DNTT ETV6 KIT
18 respiratory system MP:0005388 9.43 CBFB CREBBP CSF1 KIT MYH11 RUNX1
19 skeleton MP:0005390 9.23 CBFB CREBBP CSF1 CSF1R FLT3 KIT

Drugs & Therapeutics for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils...

Drugs for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22) (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 217)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
2
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 6055-19-2, 50-18-0 2907
3
Thiotepa Approved, Investigational Phase 4,Phase 2,Phase 1 52-24-4 5453
4 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1
5 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
6 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
7 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1
8 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
9 Antilymphocyte Serum Phase 4,Phase 2
10
Idarubicin Approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58957-92-9 42890
11
Daunorubicin Approved Phase 3,Phase 2,Phase 1 20830-81-3 30323
12
Mitoxantrone Approved, Investigational Phase 3,Phase 2,Phase 1 65271-80-9 4212
13
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1 55-98-1 2478
14
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
15
Cytarabine Approved, Experimental, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 147-94-4, 65-46-3 6253
16
Mesna Approved, Investigational Phase 3 3375-50-6 598
17
Sargramostim Approved, Investigational Phase 3,Phase 2,Phase 1 123774-72-1, 83869-56-1
18
Aldesleukin Approved Phase 3,Phase 1,Phase 2 85898-30-2, 110942-02-4
19
Thioguanine Approved Phase 3,Phase 1 154-42-7 2723601
20
Amsacrine Approved, Investigational Phase 3 51264-14-3 2179
21
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
22
Clofarabine Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 123318-82-1 119182
23
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
24
Caspofungin Approved Phase 3 179463-17-3, 162808-62-0 2826718 468682
25
Fludarabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 75607-67-9, 21679-14-1 30751
26
Methotrexate Approved Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
27
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
28
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 1 1177-87-3
29
leucovorin Approved Phase 3,Phase 2,Phase 1 58-05-9 6006 143
30
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 1 50-02-2 5743
31
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
32
Arsenic trioxide Approved, Investigational Phase 2, Phase 3,Phase 1 1327-53-3 518740
33
alemtuzumab Approved, Investigational Phase 2, Phase 3,Phase 1 216503-57-0
34
Azacitidine Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 320-67-2 9444
35
Melphalan Approved Phase 2, Phase 3,Phase 3,Phase 1 148-82-3 460612 4053
36
Carmustine Approved, Investigational Phase 3 154-93-8 2578
37
Hydroxyurea Approved Phase 3 127-07-1 3657
38
Decitabine Approved, Investigational Phase 3,Phase 2,Phase 1 2353-33-5 451668
39
midostaurin Approved, Investigational Phase 3,Phase 2 120685-11-2 9829523 104937
40
Histamine Approved, Investigational Phase 3 51-45-6 774
41
Cyproheptadine Approved Phase 3 129-03-3 2913
42
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 2,Phase 1 302-79-4 5538 444795
43
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
44
tipifarnib Investigational Phase 3,Phase 2,Phase 1 192185-72-1 159324
45 Staurosporine Experimental Phase 3,Phase 2,Phase 1 62996-74-1
46 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
47 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
48 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
49 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
50 Analgesics Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 195)
# Name Status NCT ID Phase Drugs
1 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
2 Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia Unknown status NCT00002549 Phase 3 busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mesna;mitoxantrone hydrochloride
3 Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission Unknown status NCT00454168 Phase 3
4 Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia Unknown status NCT00006045 Phase 3 cytarabine;etoposide;mitoxantrone hydrochloride
5 Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia Unknown status NCT00004128 Phase 3 busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide
6 Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Unknown status NCT00091234 Phase 2, Phase 3 gemtuzumab ozogamicin
7 Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia Unknown status NCT00002658 Phase 3 amsacrine;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin
8 Caspofungin Versus Fluconazole in Preventing Invasive Fungal Infections (IFI) in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia Completed NCT01307579 Phase 3 Caspofungin Acetate;Fluconazole
9 Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission Completed NCT00093470 Phase 3 Tipifarnib
10 Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Completed NCT00006363 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar;busulfan
11 Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT00372593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;etoposide;gemtuzumab ozogamicin;mitoxantrone hydrochloride
12 Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia Completed NCT00005863 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;fludarabine phosphate;tretinoin
13 Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00369317 Phase 3 asparaginase;daunorubicin hydrochloride;cytarabine;thioguanine;etoposide
14 Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia Completed NCT00003190 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar
15 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Completed NCT00002798 Phase 3 asparaginase;daunorubicin hydrochloride;fludarabine phosphate;therapeutic hydrocortisone;cytarabine;idarubicin;dexamethasone;thioguanine;etoposide;methotrexate;cyclophosphamide;busulfan
16 Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Completed NCT00454480 Phase 2, Phase 3 arsenic trioxide;azacitidine;busulfan;clofarabine;cytarabine;daunorubicin hydrochloride;fludarabine phosphate;gemtuzumab ozogamicin;melphalan;tipifarnib
17 Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia Completed NCT00002719 Phase 3 amsacrine;carmustine;cytarabine;etoposide;idarubicin;mitoxantrone hydrochloride
18 Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
19 Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00121303 Phase 3 cytarabine;daunorubicin hydrochloride;gemtuzumab ozogamicin
20 Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia Completed NCT00112554 Phase 3 cytarabine;laromustine
21 Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
22 Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00002517 Phase 3 cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine
23 flt3L in Treating Patients With Acute Myeloid Leukemia Completed NCT00006223 Phase 3
24 S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML Completed NCT00085709 Phase 3 gemtuzumab ozogamicin;Cytosine arabinoside;Daunomycin
25 High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Completed NCT00002945 Phase 3 cyclophosphamide;cytarabine;etoposide;idarubicin;melphalan
26 Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia Completed NCT00046930 Phase 3 cytarabine;daunorubicin hydrochloride;zosuquidar trihydrochloride;Placebo
27 Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia Completed NCT00052299 Phase 3 cytarabine;etoposide;gemtuzumab ozogamicin;idarubicin;mitoxantrone hydrochloride
28 Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting NCT02085408 Phase 3 clofarabine;daunorubicin hydrochloride;cytarabine;decitabine
29 Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting NCT00651261 Phase 3 cytarabine;daunorubicin;midostaurin;dexamethasone acetate
30 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
31 Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant Unknown status NCT02038153 Phase 1, Phase 2 Lenalidomide
32 Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia Unknown status NCT00003405 Phase 2 amifostine trihydrate;bromodeoxyuridine;cytarabine;idarubicin;idoxuridine;isotretinoin;mitoxantrone hydrochloride
33 Combination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous Leukemia Unknown status NCT00003758 Phase 2 cytarabine;idarubicin
34 Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia Unknown status NCT00838240 Phase 1, Phase 2 clofarabine;cytarabine;idarubicin
35 VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid Leukemia Unknown status NCT00354276 Phase 2 cytarabine;laromustine
36 Monoclonal Antibody in Treating Patients With Acute Myelogenous Leukemia Unknown status NCT00006084 Phase 2
37 Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia Completed NCT01870596 Phase 2 Cytarabine;CHK1 Inhibitor SCH 900776
38 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia Completed NCT01361464 Phase 2 Tipifarnib
39 High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
40 Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia Completed NCT00666588 Phase 2 idarubicin;cytarabine;bortezomib;etoposide
41 Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed NCT01664897 Phase 2 Erlotinib Hydrochloride
42 Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia Completed NCT02144675 Phase 2 choline magnesium trisalicylate;idarubicin;cytarabine
43 CPX-351 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT02019069 Phase 2 liposomal cytarabine-daunorubicin CPX-351
44 Donor Stem Cell Transplant or Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia in Remission Completed NCT01020734 Phase 2 busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;methotrexate
45 Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT01349972 Phase 2 alvocidib;daunorubicin hydrochloride;mitoxantrone hydrochloride;cytarabine
46 AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed NCT01253447 Phase 2 Akt inhibitor MK2206
47 Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy Completed NCT01235572 Phase 2
48 Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Completed NCT00372619 Phase 1, Phase 2 clofarabine;cytarabine;methotrexate
49 Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML Completed NCT00895934 Phase 1, Phase 2 vorinostat;gemtuzumab ozogamicin;azacitidine
50 Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT00795002 Phase 2 alvocidib;mitoxantrone hydrochloride;cytarabine

Search NIH Clinical Center for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22)

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Genetic Tests for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils...

Genetic tests related to Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22):

# Genetic test Affiliating Genes
1 Acute Myelomonocytic Leukemia 30

Anatomical Context for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils...

MalaCards organs/tissues related to Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22):

42
Myeloid, Bone, Bone Marrow, Monocytes, Lung, Prostate, Skin

Publications for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils...

Articles related to Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22):

(show top 50) (show all 294)
# Title Authors Year
1
Acute Myelomonocytic Leukemia Presenting as Perianal Pain. ( 30598853 )
2018
2
A Case of Granulocytic Sarcoma or Extramedullary Acute Myelomonocytic Leukemia of the Gallbladder. ( 30352989 )
2018
3
t(9;19)(q22;p13) in Acute Myelomonocytic Leukemia. ( 29391333 )
2018
4
Sequential strategy for umbilical cord blood transplantation in a Korean Fanconi anemia girl with refractory acute myelomonocytic leukemia and complex karyotype. ( 27976485 )
2017
5
Clinical and prognostic significance of eosinophilia and inv(16)/t(16;16) in pediatric acute myelomonocytic leukemia (AML-M4). ( 28371234 )
2017
6
NUP98 Rearrangement in Acute Myelomonocytic Leukemia With t(11;19)(p15;p12): The First Case Report Worldwide. ( 28224778 )
2017
7
Facial Diplegia as Initial Manifestation of Acute, Myelomonocytic Leukemia with Isolated Trisomy 47, XY,+11[14]/46, XY[6]. ( 28694633 )
2017
8
Orbital myxoma comorbid with acute myelomonocytic leukemia. ( 28812920 )
2017
9
Presentation of Gallbladder Chloroma in B-Mode Imaging and Contrast-Enhanced Ultrasound (CEUS) in a Patient with Acute Myelomonocytic Leukemia (AML M5). ( 29226275 )
2017
10
Human NUP98-IQCG fusion protein induces acute myelomonocytic leukemia in mice by dysregulating the Hox/Pbx3 pathway. ( 26675333 )
2016
11
Acute myelomonocytic leukemia and leukocytoclastic vasculitis. ( 28029561 )
2016
12
Identification of a Cryptic Insertion ins(11;X)(q23;q28q12) Resulting in a KMT2A-FLNA Fusion in a 13-Month-Old Child with Acute Myelomonocytic Leukemia. ( 28253492 )
2016
13
Cardiopulmonary Failure Requiring ECMO Bypass Resulting from Leukemia Cell Lysis in a Patient with Childhood Acute Myelomonocytic Leukemia. ( 26124967 )
2015
14
A novel mutation of SETBP1 in atypical chronic myeloid leukemia transformed from acute myelomonocytic leukemia. ( 26185647 )
2015
15
MLL-ELL fusion gene in an acute myelomonocytic leukemia patient transformed from acute promyelocytic leukemia. ( 26185637 )
2015
16
Cochlear implantation in a patient with acute myelomonocytic leukemia before allogeneic peripheral blood stem cell transplantation. ( 24560096 )
2014
17
Targeted ex vivo reduction of CD64-positive monocytes in chronic myelomonocytic leukemia and acute myelomonocytic leukemia using human granzyme B-based cytolytic fusion proteins. ( 24523193 )
2014
18
A novel fusion of SQSTM1 and FGFR1 in a patient with acute myelomonocytic leukemia with t(5;8)(q35;p11) translocation. ( 25501022 )
2014
19
Bilateral Adrenal Masses in a Patient in Remission From Acute Myelomonocytic Leukemia. ( 24566206 )
2014
20
RANBP2-ALK fusion combined with monosomy 7 in acute myelomonocytic leukemia. ( 24613277 )
2014
21
Interaction Between Myelomonocytic and Lymphoid Cells in a Patient with Acute MyeloMonocytic Leukemia and Chronic Lymphocytic Leukemia. ( 23987820 )
2013
22
Interdigitating dendritic cell sarcoma presenting simultaneously with acute myelomonocytic leukemia: report of a rare case and literature review. ( 23605368 )
2013
23
Leukemic ascites as an initial presentation of acute myelomonocytic leukemia with inversion of chromosome 16. ( 23563011 )
2013
24
Thrombomodulin-induced differentiation of acute myelomonocytic leukemia cells via JNK signaling. ( 22342852 )
2012
25
Acute myelomonocytic leukemia presenting with gingival enlargement as the only clinical manifestation. ( 23493961 )
2012
26
Establishment and characterization of a new human acute myelomonocytic leukemia cell line JIH-3. ( 22340903 )
2012
27
p210 BCR/ABL1 as a secondary change in a patient with acute myelomonocytic leukemia (M4Eo) with inv(16). ( 23054652 )
2012
28
Myeloid Sarcoma and Acute Myelomonocytic Leukemia in an Adolescent with Tetrasomy 8: Staging with (18)F-FDG PET/CT. ( 24900045 )
2012
29
Acute myelomonocytic leukemia (AML-M4) in a dog with the extradural lesion. ( 21060242 )
2011
30
CD7-positive acute myelomonocytic leukemia with trisomy 21 as a sole acquired chromosomal abnormality in two adolescents. ( 21592571 )
2011
31
Double supernumerary isochromosome 4p in acute myelomonocytic leukemia. ( 20863564 )
2010
32
Isolated central nervous system relapse in an adolescent with acute myelomonocytic leukemia, Charcot Marie Tooth syndrome, and paraneoplastic autoantibody. ( 20724950 )
2010
33
Myeloid sarcoma in the nasal cavities that developed during the course of acute myelomonocytic leukemia. ( 21123976 )
2010
34
Acute Shoulder Monoarthritis in a Patient With Acute Myelomonocytic Leukemia With Novel Translocation t(5;13). ( 29147181 )
2010
35
Pseudo Chediak-Higashi anomaly in acute myelomonocytic leukemia. ( 19332932 )
2009
36
Genome profiling of acute myelomonocytic leukemia: alteration of the MYB locus in MYST3-linked cases. ( 18818702 )
2009
37
Gemtuzumab ozogamicin-induced long-term remission in a woman with acute myelomonocytic leukemia and bone marrow relapse following allogeneic transplantation. ( 19904520 )
2009
38
Treatment-related acute myelomonocytic leukemia with t(11;19) in a child following chemotherapy for hepatoblastoma. ( 17973320 )
2008
39
A dog with acute myelomonocytic leukemia. ( 18628605 )
2008
40
Systemic mastocytosis with acute myelomonocytic leukemia: a case report. ( 23100960 )
2008
41
Comparative analysis of genes regulated in acute myelomonocytic leukemia with and without inv(16)(p13q22) using microarray techniques, real-time PCR, immunohistochemistry, and flow cytometry immunophenotyping. ( 17571080 )
2007
42
Mesenteric chloroma with t(16;16) followed by acute myelomonocytic leukemia with clonal evolution. ( 18036407 )
2007
43
Rare t(1;11)(q23;p15) in therapy-related myelodysplastic syndrome evolving into acute myelomonocytic leukemia: a case report and review of the literature. ( 17889707 )
2007
44
Parotid involvement in acute myelomonocytic leukemia. ( 17978464 )
2007
45
[Depressing the immune escape of acute myelomonocytic leukemia via an anti-Fas ribozyme]. ( 17096877 )
2006
46
Establishment of a stroma-dependent human acute myelomonocytic leukemia cell line, NAMO-2, with FLT3 tandem duplication. ( 17118759 )
2006
47
Dup(1)(p31.2p36.2) in acute myelomonocytic leukemia. ( 16490603 )
2006
48
Acute myelomonocytic leukemia in a boy with LEOPARD syndrome (PTPN11 gene mutation positive). ( 16679933 )
2006
49
Acute myelomonocytic leukemia with abnormal eosinophils: a case report with multi-modality diagnostic work-up. ( 17214400 )
2006
50
[Immunophenotypic and cytogenetic features of acute myelomonocytic leukemia]. ( 17059770 )
2006

Variations for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils...

Expression for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils...

Search GEO for disease gene expression data for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22).

Pathways for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils...

Pathways related to Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22) according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.04 CREBBP CSF1 CSF1R KIT MYH11
2
Show member pathways
12.74 CREBBP CSF1 CSF1R FLT3 KIT
3 12.6 CREBBP CSF1R FLT3 KIT RUNX1
4
Show member pathways
12.54 CREBBP CSF1R FLT3 KIT MPO RUNX1
5 12.53 CSF1 CSF1R FLT3 KIT
6
Show member pathways
12.48 CSF1 CSF1R FLT3 KIT
7 11.89 CSF1R FLT3 KIT
8 11.77 CSF1 FLT3 KIT MPO
9 11.45 CREBBP CSF1R KIT MPO
10 11.37 CSF1R ETV6 FLT3 KMT2A MPO RUNX1
11 11.34 CSF1 CSF1R DNTT FLT3 KIT
12 11.33 CSF1 CSF1R FLT3 KIT
13 11.31 CSF1 CSF1R KIT
14
Show member pathways
11.23 CREBBP CSF1 CSF1R
15 10.89 CREBBP ETV6 FLT3
16 10.77 CSF1 CSF1R FLT3 KIT
17 10.73 CSF1 MPO
18 10.45 CBFB RUNX1

GO Terms for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils...

Cellular components related to Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22) according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 receptor complex GO:0043235 9.33 CSF1R FLT3 KIT
2 core-binding factor complex GO:0016513 8.96 CBFB RUNX1
3 CSF1-CSF1R complex GO:1990682 8.62 CSF1 CSF1R

Biological processes related to Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22) according to GeneCards Suite gene sharing:

(show all 32)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.93 CSF1 CSF1R FLT3 KIT
2 positive regulation of cell migration GO:0030335 9.83 CSF1 CSF1R KIT
3 cytokine-mediated signaling pathway GO:0019221 9.81 CSF1 CSF1R FLT3 KIT
4 peptidyl-tyrosine phosphorylation GO:0018108 9.79 CSF1R FLT3 KIT
5 protein autophosphorylation GO:0046777 9.79 CSF1R FLT3 KIT
6 cell differentiation GO:0030154 9.78 CSF1 ETV6 FLT3
7 positive regulation of MAPK cascade GO:0043410 9.77 CSF1R FLT3 KIT
8 transcription by RNA polymerase II GO:0006366 9.65 CBFB KMT2A
9 negative regulation of apoptotic process GO:0043066 9.65 CSF1R MPO
10 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.65 CSF1R FLT3 KIT
11 regulation of Wnt signaling pathway GO:0030111 9.64 CBFB RUNX1
12 osteoclast differentiation GO:0030316 9.63 CSF1 CSF1R
13 regulation of megakaryocyte differentiation GO:0045652 9.63 CBFB KMT2A RUNX1
14 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.62 FLT3 KIT
15 macrophage differentiation GO:0030225 9.59 CSF1 CSF1R
16 embryonic hemopoiesis GO:0035162 9.58 KIT KMT2A
17 regulation of intracellular estrogen receptor signaling pathway GO:0033146 9.58 CBFB RUNX1
18 regulation of keratinocyte differentiation GO:0045616 9.57 CBFB RUNX1
19 regulation of regulatory T cell differentiation GO:0045589 9.56 CBFB RUNX1
20 hematopoietic stem cell proliferation GO:0071425 9.55 ETV6 RUNX1
21 regulation of bicellular tight junction assembly GO:2000810 9.54 CBFB RUNX1
22 regulation of B cell receptor signaling pathway GO:0050855 9.52 CBFB RUNX1
23 regulation of cytokine-mediated signaling pathway GO:0001959 9.49 CBFB RUNX1
24 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.46 CSF1 CSF1R FLT3 KIT
25 myeloid progenitor cell differentiation GO:0002318 9.43 FLT3 KIT
26 regulation of hematopoietic stem cell differentiation GO:1902036 9.43 CBFB KMT2A RUNX1
27 macrophage colony-stimulating factor signaling pathway GO:0038145 9.4 CSF1 CSF1R
28 negative regulation of CD4-positive, alpha-beta T cell differentiation GO:0043371 9.37 CBFB RUNX1
29 positive regulation of CD8-positive, alpha-beta T cell differentiation GO:0043378 9.32 CBFB RUNX1
30 regulation of myeloid cell differentiation GO:0045637 9.13 CBFB CREBBP RUNX1
31 hemopoiesis GO:0030097 9.02 CSF1 CSF1R FLT3 KIT RUNX1
32 positive regulation of transcription by RNA polymerase II GO:0045944 10.04 CBFB CREBBP ETV6 KMT2A RUNX1

Molecular functions related to Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils Inv(16)(p13q22) or T(16;16)(p13;q22) according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transferase activity GO:0016740 9.8 CREBBP CSF1R DNTT FLT3 KIT KMT2A
2 DNA-binding transcription factor activity GO:0003700 9.46 CBFB ETV6 KMT2A RUNX1
3 protein tyrosine kinase activity GO:0004713 9.43 CSF1R FLT3 KIT
4 cytokine binding GO:0019955 9.4 CSF1R KIT
5 protein homodimerization activity GO:0042803 9.35 CSF1 CSF1R FLT3 KIT KMT2A
6 transmembrane receptor protein tyrosine kinase activity GO:0004714 8.8 CSF1R FLT3 KIT
7 protein binding GO:0005515 10.11 CBFB CREBBP CSF1 CSF1R DNTT ETV6

Sources for Acute Myeloid Leukemia with Abnormal Bone Marrow Eosinophils...

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....